lulizumab pegol
mAbexperimental
Lulizumab pegol is a monoclonal antibody developed by Bristol-Myers Squibb for the treatment of autoimmune diseases such as cutaneous lupus erythematosus. — Wikipedia
Clinical trial activity
5 trials · 6 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
4
Phase 3
0
Phase 4
0
Earliest trial started Nov 13, 2014 (NCT02265744)
Timeline
Indications
Mechanism of action
CD28 antagonist
CD28 inhibitor
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaLulizumab pegol ↗
- ChEMBLCHEMBL3137354 ↗
Also known as
- bms-931699
- bms-931699
- bms-931699
- lulizumab pegol
- lulizumab pegol
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04903054 | Phase 2 | Oct 31, 2021 | Bristol-Myers Squibb, Emory University, National Institute of Allergy and Infectious Diseases (NIAID), PPD |
| NCT04066114 | Phase 1/Phase 2 (Phase 2) | Oct 31, 2019 | Bristol-Myers Squibb, Clinical Trials in Organ Transplantation, National Institute of Allergy and Infectious Diseases (NIAID), University of California, San Francisco |
| NCT03058822 | Phase 1 | Feb 1, 2017 | Bristol-Myers Squibb |
| NCT02843659 | Phase 2 | Oct 18, 2016 | Bristol-Myers Squibb |
| NCT02265744 | Phase 2 | Nov 13, 2014 | Bristol-Myers Squibb |
Showing 5 of 5 trials
Page 1 / 1
Organizations
Research & Development (6)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Bristol-Myers Squibb | For profit | 5 | 3 | 2 | 2014 |
| National Institute of Allergy and Infectious Diseases (NIAID) | Government | 2 | 2 | 1 | 2019 |
| Clinical Trials in Organ Transplantation | Government | 1 | 0 | 1 | 2019 |
| Emory University | Academic/Hospital | 1 | 0 | 1 | 2021 |
| PPD | For profit | 1 | 0 | 1 | 2021 |
| University of California, San Francisco | Academic/Hospital | 1 | 0 | 1 | 2019 |
6 organizations
Page 1 / 1